Hikma Pharmaceuticals PLC Stock price

Equities

HIK

GB00B0LCW083

Pharmaceuticals

Market Closed - London S.E. 12:35:27 2024-03-28 pm EDT 5-day change 1st Jan Change
1,918 GBX +2.02% Intraday chart for Hikma Pharmaceuticals PLC +2.40% +7.24%
Sales 2024 * 2.94B Sales 2025 * 3.06B Capitalization 5.27B
Net income 2024 * 419M Net income 2025 * 450M EV / Sales 2024 * 2.05 x
Net Debt 2024 * 779M Net Debt 2025 * 556M EV / Sales 2025 * 1.9 x
P/E ratio 2024 *
12.5 x
P/E ratio 2025 *
12.1 x
Employees 9,100
Yield 2024 *
2.99%
Yield 2025 *
3.07%
Free-Float 65.5%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Hikma Pharmaceuticals PLC

1 day+0.65%
1 week-3.47%
Current month-4.40%
1 month-5.53%
3 months+5.79%
6 months-10.15%
Current year+5.11%
More quotes
1 week
1 855.00
Extreme 1855
1 922.50
1 month
1 823.50
Extreme 1823.5
1 992.00
Current year
1 770.50
Extreme 1770.5
2 165.00
1 year
1 614.50
Extreme 1614.5
2 222.00
3 years
1 174.50
Extreme 1174.5
2 703.00
5 years
1 174.50
Extreme 1174.5
2 768.00
10 years
814.20
Extreme 814.2
2 768.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 89-12-31
Director of Finance/CFO 52 00-12-31
Chairman 66 80-12-31
Members of the board TitleAgeSince
Director/Board Member 66 20-04-30
Director/Board Member 72 16-09-30
Director/Board Member 62 22-10-31
More insiders
Date Price Change Volume
24-03-28 1,918 +2.02% 332 600
24-03-27 1,880 +0.86% 300,689
24-03-26 1,864 -0.98% 431,871
24-03-25 1,883 -1.70% 876,861
24-03-22 1,916 +2.24% 677,775

Delayed Quote London S.E., March 27, 2024 at 12:35 pm EDT

More quotes
Hikma Pharmaceuticals PLC specializes in developing, producing, and selling drugs used in treating cardiovascular diseases, infections, cancers, diabetes, etc. Net sales break down by family of products as follows: - generic injectable products (45.3%); - brand name drugs (27.5%); - generic products taken orally (26.7%); - other (0.5%). Net sales are distributed geographically as follows: the United Kingdom (0.3%), the United States (56.9%), Middle East and North Africa (34.4%) and other (8.4%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
23.74 USD
Average target price
29.18 USD
Spread / Average Target
+22.89%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Hikma Pharmaceuticals PLC - London S.E.